Showing results (61-70 of 73) with videos related to

Sort By:
Pageof 8
Genes & Development|October 18, 2023
MYC acetylated lysine residues drive oncogenic cell transformation and regulate select genetic programs for cell adhesion-independent growth and survivalMatthew Hurd, Jeffrey Pino, Kay Jang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 30, 2019
Addition of Docetaxel to Oral Fluoropyrimidine Improves Efficacy in Patients With Stage III Gastric Cancer: Interim Analysis of JACCRO GC-07, a Randomized Controlled TrialKazuhiro Yoshida, Yasuhiro Kodera, Mitsugu Kochi, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|August 24, 2021
Real-world effectiveness of nivolumab in advanced gastric cancer: the DELIVER trial (JACCRO GC-08)Yoshikazu Takahashi, Yu Sunakawa, Eisuke Inoue, et al.
Nature Communications|November 25, 2024
Modified FOLFOXIRI plus cetuximab versus bevacizumab in RAS wild-type metastatic colorectal cancer: a randomized phase II DEEPER trialManabu Shiozawa, Yu Sunakawa, Takanori Watanabe, et al.
Clinical Colorectal Cancer|September 17, 2018
Immune-related Genes to Dominate Neutrophil-lymphocyte Ratio (NLR) Associated With Survival of Cetuximab Treatment in Metastatic Colorectal CancerYu Sunakawa, Dongyun Yang, Shu Cao, et al.
Molecular Cancer Therapeutics|October 3, 2018
Tumor Sidedness and Enriched Gene Groups for Efficacy of First-line Cetuximab Treatment in Metastatic Colorectal CancerYu Sunakawa, Kaoru Mogushi, Heinz-Josef Lenz, et al.
International Journal of Cancer|June 2, 2017
Predictive value of TLR7 polymorphism for cetuximab-based chemotherapy in patients with metastatic colorectal cancerSatoshi Okazaki, Sebastian Stintzing, Yu Sunakawa, et al.
Targeted Oncology|April 15, 2023
A Multicenter, Phase II Trial of Schedule Modification for Nab-Paclitaxel in Combination with Ramucirumab for Patients with Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer: The B-RAX Trial (JACCRO GC-09)Ryohei Kawabata, Naoki Izawa, Takahisa Suzuki, et al.
British Journal of Cancer|September 1, 2020
Phase 2 study of irinotecan plus cetuximab rechallenge as third-line treatment in KRAS wild-type metastatic colorectal cancer: JACCRO CC-08Toshiki Masuishi, Akihito Tsuji, Masahito Kotaka, et al.
Cancer Biology & Therapy|April 23, 2016
Combined assessment of EGFR-related molecules to predict outcome of 1st-line cetuximab-containing chemotherapy for metastatic colorectal cancerYu Sunakawa, Dongyun Yang, Miriana Moran, et al.
Pageof 8